Vir Biotechnology reports positive hepatitis results, early signs of possible cure
PonyWang/E+ via Getty Images
Vir Biotechnology (VIR) said Sunday that its experimental combination treatment for chronic hepatitis delta met its primary goal in a phase 3 clinical trial, while separate phase 2 results showed sustained suppression of the virus in patients who stopped treatment.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.